Pα+ Psychedelic Bulletin #229: SAMHSA Convenes Experts; AtaiBeckley’s Road to Lilly; Turnbull Doubles Down on BOL-148; Compass Talks Indication Expansion, Could VA Help?
- New: Listen to this Bulletin
- SAMHSA Convenes Experts to Tackle Psychedelic Data Gaps
- Compass Talks REMS, Indication Expansion, Silent on Usona
- AtaiBeckley’s Road to Lilly: Ibogaine Carve-Outs, and Counteroffers
- VA-Assisted Label Expansion?
- Turnbull Doubles Down on Non-Hallucinogenic LSD
- Other Stories
SAMHSA Convenes Experts to Tackle Psychedelic Data Gaps
Dozens of experts met in D.C. last week under the auspices of SAMHSA’s two-day consultation, titled ‘Addressing Data Gaps to Monitor the Expanding Use and Misuse of Psychedelics in the U.S.’.
Attendees included federal agency representatives as well as psychedelic researchers, state regulators, and entrepreneurs. Drug development companies were not invited.
We cannot disclose the contents of that meeting, though attendees explored the current ‘mosaic’ of data sources surrounding psychedelic use (both in regulated and unregulated contexts) and identified potential gaps, opportunities to harmonise data collection and reporting methods, and future areas of potential work.
Our editor, Josh Hardman, delivered a brief presentation on the emerging regulated landscape of psychedelic use and the data that (may) emerge therefrom, with a focus on the U.S. but also international regulated access pathways, such as those in Australia, ...
Join Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.
- Regular Bulletins featuring news, analysis, and research
- Articles and deep dives across psychedelic drug development, policy, and research
- Exclusive interviews with researchers, executives, and policymakers
- Bespoke resources and tools including the Psychedelic Bill Tracker
- Quarterly video briefings and slide decks